Try our Advanced Search for more refined results
Daiichi Sankyo, Inc. et al. Post grant review
Case Number:
Case Type:
PGR
Status:
Trial Instituted
Petitioner:
Daiichi Sankyo, Inc. et al.
Patent Owner:
Tech Center:
-
Filed: December 23, 2020 00:00
Coverage
-
January 17, 2024
PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict
The Patent Trial and Appeal Board has said Daiichi Sankyo was able to show that the challenged claims of a Seagen cancer drug patent, which a Texas federal jury found Daiichi infringed in a $42 million verdict in 2022, were invalid.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Search PTAB cases and full-text documents.
- Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
- Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the PTAB case documentsAlready a subscriber? Click here to login
-
January 17, 2024